Related Experiment Video
Updated: Apr 18, 2026
Y-27632 Enriches the Yield of Human Melanocytes from Adult Skin Tissues
Published on: July 8, 2020
Quantification of a Pharmacodynamic ERK End Point in Melanoma Cell Lysates: Toward Personalized Precision Medicine
Mangalika Warthaka1, Charles H Adelmann2, Tamer S Kaoud3
1Division of Medicinal Chemistry, College of Pharmacy, Department of Biomedical Engineering, and Department of Chemistry, The University of Texas , Austin, Texas 78712, United States.
Abstract:
Protein kinases are mutated or otherwise rendered constitutively active in numerous cancers where they are attractive therapeutic targets with well over a dozen kinase inhibitors now being used in therapy. While fluorescent sensors have capacity to measure changes in kinase activity, surprisingly they have not been utilized for biomarker studies. A first-generation peptide sensor for ERK based on the Sox fluorophore is described. This sensor called ERK-sensor-D1 possesses high activity toward ERK and more than 10-fold discrimination over other MAPKs. The sensor can rapidly quantify ERK activity in cell lysates and monitor ERK pathway engagement by BRAF and MEK inhibitors in cultured melanoma cell lines. The dynamic range of the sensor assay allows ERK activities that have potential for profound clinical consequences to be rapidly distinguished.
Insights
A novel fluorescent peptide sensor, ERK-sensor-D1, accurately measures ERK activity. This tool distinguishes clinically relevant ERK levels and monitors inhibitor effectiveness in cancer cells.
Area of Science:
- Biochemistry
- Molecular Biology
- Cancer Therapeutics
Background:
- Protein kinases are crucial in cancer development and are key therapeutic targets.
- Kinase inhibitors are widely used, but sensitive biomarker tools for activity monitoring are lacking.
- Fluorescent sensors offer potential for kinase activity measurement but are underutilized in biomarker studies.
Purpose of the Study:
- To develop and characterize a novel fluorescent peptide sensor for quantifying Extracellular signal-Regulated Kinase (ERK) activity.
- To assess the sensor's specificity and utility in monitoring kinase pathway engagement by therapeutic inhibitors.
Main Methods:
- A first-generation peptide sensor (ERK-sensor-D1) utilizing the Sox fluorophore was designed.
- The sensor's activity and specificity against various MAPKs were evaluated.
- ERK activity was quantified in cell lysates and monitored in melanoma cell lines treated with BRAF and MEK inhibitors.
Main Results:
- ERK-sensor-D1 demonstrated high activity toward ERK with over 10-fold discrimination against other MAPKs.
- The sensor rapidly quantified ERK activity in cell lysates.
- The assay successfully monitored ERK pathway inhibition by BRAF and MEK inhibitors in melanoma cells.
Conclusions:
- The developed ERK sensor is a valuable tool for quantifying ERK activity and monitoring therapeutic responses.
- This sensor has the potential for biomarker studies due to its dynamic range and specificity.
- The tool can rapidly distinguish ERK activity levels with significant clinical implications.
